Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Badoux

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Leukemia & Lymphoma|June 21, 2017
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of managementBronwyn C Thorp, Xavier Badoux
Blood|May 15, 2015
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)Philip Young-Ill Choi, Fernando Roncolato, Xavier Badoux, et al.
Advances in Therapy|October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical DevelopmentAndrew Davies, Claude Berge, Axel Boehnke, et al.
British Journal of Clinical Pharmacology|April 23, 2015
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemiaSarit Assouline, Valeria Buccheri, Alain Delmer, et al.
Human Pathology|July 8, 2011
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3Xavier Badoux, Carlos Bueso-Ramos, David Harris, et al.
The Lancet. Haematology|March 8, 2016
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trialSarit Assouline, Valeria Buccheri, Alain Delmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Cancer|August 23, 2011
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaBang-Ning Lee, Hui Gao, Evan N Cohen, et al.
Blood|July 14, 2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemiaSameer A Parikh, Michael J Keating, Susan O'Brien, et al.
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|June 21, 2017
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of managementBronwyn C Thorp, Xavier Badoux
Blood|May 15, 2015
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)Philip Young-Ill Choi, Fernando Roncolato, Xavier Badoux, et al.
Advances in Therapy|October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical DevelopmentAndrew Davies, Claude Berge, Axel Boehnke, et al.
British Journal of Clinical Pharmacology|April 23, 2015
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemiaSarit Assouline, Valeria Buccheri, Alain Delmer, et al.
Human Pathology|July 8, 2011
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3Xavier Badoux, Carlos Bueso-Ramos, David Harris, et al.
The Lancet. Haematology|March 8, 2016
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trialSarit Assouline, Valeria Buccheri, Alain Delmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Cancer|August 23, 2011
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaBang-Ning Lee, Hui Gao, Evan N Cohen, et al.
Blood|July 14, 2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemiaSameer A Parikh, Michael J Keating, Susan O'Brien, et al.
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
Pageof 2